Ilumya Overview:

Ilumya (tildrakizumab-asmn) is a biologic therapy indicated for the treatment of moderate-to-severe plaque psoriasis in adults. It works by targeting specific proteins in the immune system to reduce inflammation and improve skin health.

What Is Ilumya?

Ilumya is an injectable biologic medication approved by the FDA for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The active ingredient, tildrakizumab, is a monoclonal antibody that inhibits the p19 subunit of interleukin-23 (IL-23), a key protein involved in the inflammatory process of psoriasis.

How Ilumya Works:

Ilumya works by blocking IL-23, a cytokine that plays a crucial role in the pathogenesis of plaque psoriasis. By inhibiting IL-23, Ilumya helps to reduce the inflammation and proliferation of skin cells that lead to the formation of psoriatic plaques.

What Is Ilumya Used For?

Ilumya is prescribed to manage:

Moderate-to-severe plaque psoriasis in adults.
Ilumya Injection Administration and Dosing:
Administration:

Ilumya is administered via subcutaneous injection by a healthcare professional. It is important that patients receive their injections in a medical setting to ensure proper administration and monitoring.

Dosage and Frequency:

Initial Dose: Patients receive an initial dose of 100 mg of Ilumya.
Follow-Up Dose: A second dose of 100 mg is administered four weeks after the initial dose.
Maintenance Dose: Following the first two doses, patients receive a maintenance dose of 100 mg every 12 weeks.
Side Effects of Ilumya Injections:
As with any medication, Ilumya can cause side effects. It is important for patients to be aware of potential side effects and to communicate any concerns with their healthcare provider.

Common Side Effects:

Upper respiratory infections
Injection site reactions (e.g., redness, swelling, pain)
Diarrhea
Headache

Serious Side Effects:

Infections: Patients may be at an increased risk for infections. Symptoms to watch for include fever, chills, sweats, muscle aches, cough, shortness of breath, and blood in phlegm.
Allergic Reactions: Symptoms may include rash, itching, swelling, severe dizziness, and trouble breathing.
Tuberculosis (TB): Ilumya may increase the risk of reactivation of latent tuberculosis. Patients should be screened for TB before starting treatment and monitored during therapy.
How To Prepare for an Ilumya Injection:
Before starting Ilumya, patients should:

Undergo screening for tuberculosis and other infections.
Inform their healthcare provider of any existing health conditions, including history of infections and any current medications being taken.
Discuss any allergies, particularly to medications.
How to Get a Referral for Ilumya Injections:
A referral for Ilumya must be accompanied by a physician’s order for treatment.

Patient information should include:

Name
Current address
Home and mobile phone number
Insurance information
Information the physician must include on the patient’s order for Ilumya injection therapy:

Patient’s name and date of birth
Order date
Diagnosis
Physician’s name and NPI#
Office address, phone, and fax numbers
Provider’s signature
Supporting clinical documentation from the physician should include:

Empowering Psoriasis Management with Ilumya:

Ilumya offers a targeted treatment option for adults with moderate-to-severe plaque psoriasis. By inhibiting IL-23, Ilumya helps to control the symptoms of psoriasis and improve skin health, providing a valuable tool for individuals seeking relief from this chronic condition.